Recursion Pharmaceuticals, a small-cap biotech company, is utilizing AI technology to accelerate drug development. However, it has yet to show concrete results with no products on the market or in phase 3 studies. On the other hand, Eli Lilly, a well-established pharmaceutical company, is investing in AI and has a solid track record of revenue growth. Investing in Eli Lilly may be a safer option to capitalize on AI in drug discovery. The Motley Fool Stock Advisor team does not currently recommend buying stock in Recursion Pharmaceuticals, citing other potential high-return stocks.

Read more at Nasdaq, Inc.: Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.